Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine).
Phase of Trial: Phase IV
Latest Information Update: 14 Apr 2012
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 14 Apr 2012 Status changed from recruiting to discontinued as reported by EudraCT.
- 22 Mar 2012 New trial record